Extended-release metformin in patients with prediabetes, chronic heart failure and abdominal obesity in light of the effect on fat depot compartments and glucose metabolism parameters
| Autor: | O. V. Tsygankova, N. E. Apartseva, L. D. Latyntseva, A. N. Ryabikov |
|---|---|
| Jazyk: | English<br />Russian |
| Rok vydání: | 2024 |
| Předmět: | |
| Zdroj: | Сахарный диабет, Vol 27, Iss 4, Pp 357-367 (2024) |
| Druh dokumentu: | article |
| ISSN: | 2072-0351 2072-0378 |
| DOI: | 10.14341/DM13189 |
| Popis: | BACKGROUND: Considering the role of visceral adipose tissue deposition in the pathogenesis of heart failure with preserved ejection fraction (HFpEF) and the positive effect of metformin on weight loss, the effect of this drug on adipose tissue compartments in patients with HFpEF is interest.AIM: To study the effect of extended-release metformin (XR) on various fat depots and parameters of insulin-glucose homeostasis in patients with HFpEF, prediabetes and abdominal obesity (AO).MATERIALS AND METHODS: Study design: single-center, open-ended, randomized, prospective, controlled. The registration numbers of the study in the NARNIS register RNI.25.004. The study included 64 people (50% men, median age 58 [55.25; 59.75] years) with HFpEF, prediabetes and AO. All patients (groups A and B) received optimal HFpEF therapy. In group A (n=32), metformin XR 1000–1500 mg/day was additionally prescribed. All patients underwent general clinical examination, calculation of insulin resistance indices, ultrasound lipometry to determine the thickness of epicardial, preperitoneal and subcutaneous fat initially and after 6 months.RESULTS: In group A patients, there was a decrease in waist circumference by 0.9% (p=0.002), hip circumference by 1.25% (p=0.001), body weight by 4.7% (p |
| Databáze: | Directory of Open Access Journals |
| Externí odkaz: |
|